204 related articles for article (PubMed ID: 2958852)
1. Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer.
Denis L; Keuppens F; Mahler C; Debruyne FM; Weil EH; Lunglmayr G; Newling D; Robinson MR; Richards B; Smith PH
Prog Clin Biol Res; 1987; 243A():221-7. PubMed ID: 2958852
[No Abstract] [Full Text] [Related]
2. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
Lukkarinen O; Kontturi M
Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
[TBL] [Abstract][Full Text] [Related]
3. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Lamberts SW; Uitterlinden P; de Jong FH
Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
[TBL] [Abstract][Full Text] [Related]
4. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
[TBL] [Abstract][Full Text] [Related]
5. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
6. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
[TBL] [Abstract][Full Text] [Related]
7. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
Dijkman GA; Fernandez del Moral P; Plasman JW; Pull HC; van der Meijden AP; Debruyne FM; Hutchinson FG; Furr BJ
Eur Urol; 1990; 18 Suppl 3():22-5. PubMed ID: 2151271
[TBL] [Abstract][Full Text] [Related]
8. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
[TBL] [Abstract][Full Text] [Related]
9. [Zoladex in prostatic carcinoma].
Di Silverio F; Serio M
Drugs Exp Clin Res; 1990; 16 Suppl():19-29. PubMed ID: 2150501
[No Abstract] [Full Text] [Related]
10. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
Ahmed SR; Grant J; Shalet SM; Howell A; Chowdhury SD; Weatherson T; Blacklock NJ
Br Med J (Clin Res Ed); 1985 Jan; 290(6463):185-7. PubMed ID: 3155636
[TBL] [Abstract][Full Text] [Related]
11. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy.
Grant JB; Ahmed SR; Shalet SM; Costello CB; Howell A; Blacklock NJ
Br J Urol; 1986 Oct; 58(5):539-44. PubMed ID: 2946356
[TBL] [Abstract][Full Text] [Related]
12. [Lack of effect of therapy with LHRH analogs, alone or associated with flutamide, on prolactin levels in advanced prostatic carcinoma].
Banchini A; Zavaroni D; Tarditi E; Cortellini P; Ziveri M; Polotti R; Stefani F; Valenti G
Minerva Endocrinol; 1989; 14(3):165-8. PubMed ID: 2533662
[TBL] [Abstract][Full Text] [Related]
13. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
Hjertberg H; Varenhorst E; Svensson M; Kågedal B; Nordenskjöld B
Acta Oncol; 1988; 27(4):361-4. PubMed ID: 2974290
[TBL] [Abstract][Full Text] [Related]
14. Selected advances in therapy of urologic cancer--luteinizing hormone releasing hormone (LHRH) and biologic response modifier (BUR).
Javadpour N
Prog Clin Biol Res; 1988; 277():27-38. PubMed ID: 2973069
[No Abstract] [Full Text] [Related]
15. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
Debruyne FM; Denis L; Lunglmayer G; Mahler C; Newling DW; Richards B; Robinson MR; Smith PH; Weil EH; Whelan P
J Urol; 1988 Oct; 140(4):775-7. PubMed ID: 2971119
[TBL] [Abstract][Full Text] [Related]
16. Re: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. A. V. Kaisary et al. Br. J. Urol., 67, 502-508, 1991.
Bunce C
Br J Urol; 1992 Apr; 69(4):441-2. PubMed ID: 1533812
[No Abstract] [Full Text] [Related]
17. A comparison between surgical orchidectomy and the LHRH agonist 'Zoladex' (ICI 188630) in the treatment of metastatic cancer of the prostate.
Peeling WB
Prog Clin Biol Res; 1989; 303():41-5. PubMed ID: 2528738
[No Abstract] [Full Text] [Related]
18. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
Kotake T; Usami M; Sonoda T; Matsuda M; Okajima E; Osafune M; Isurugi K; Akaza H; Saitoh Y
Am J Clin Oncol; 1988; 11 Suppl 2():S108-11. PubMed ID: 2977262
[TBL] [Abstract][Full Text] [Related]
19. Goserelin--depot preparation of LHRH analogue used in the treatment of endometriosis.
Shaw RW
Prog Clin Biol Res; 1990; 323():383-92. PubMed ID: 2137621
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable sustained release formulation of the LH-RH analogue 'Zoladex' for the treatment of hormone-responsive tumours.
Furr BJ; Hutchinson FG
Prog Clin Biol Res; 1985; 185A():143-53. PubMed ID: 3162174
[No Abstract] [Full Text] [Related]
[Next] [New Search]